ANTIBODIES TO BENZO[A]PYRENE AND ESTRADIOL AND THE GENE POLYMORPHISMS OF CYTOKINES AT MALE LUNG CANCER
- Authors: Glushkov A.N.1,2, Polenok E.G.1, Gordeeva L.A.1, Mun S.A.1, Kostyanko M.V.2, Titov V.A.3, Voronina E.N.4, Rogozin A.I.2, Voloshina A.I.2, Vafin I.A.5, Ragozhina S.E.5
-
Affiliations:
- The Federal Research Center of Coal and Coal chemistry SBRAS (Institute of Human Ecology)
- Kemerovo State University
- Regional Clinical Oncology Dispensary, Kemerovo
- Institute of Chemical Biology and Fundamental Medicine SB RAS
- Regional Center of Blood, Kemerovo
- Issue: Vol 21, No 2 (2018)
- Pages: 141-149
- Section: ORIGINAL ARTICLES
- Submitted: 15.04.2020
- Accepted: 15.04.2020
- Published: 15.04.2018
- URL: https://rusimmun.ru/jour/article/view/67
- ID: 67
Cite item
Full Text
Abstract
The associations of antibodies to benzo[a]pyrene and estradiol (IgG-Bp, IgG-Es) with IL1B(rs1143634, rs16944), IL1RN(VNTR, intron 2), IL4 (VNTR, intron3), IL6 (rs1800795), IL10 (rs1800896), TNFA (rs1800629, rs361525) gene polymorphisms in 228 smoking healthy men (NM) and 657 lung cancer patients (LCP)were studied. There was revealed association of gene polymorphism only of TNFA (rs1800629) with LC, but not others cytokines. LC risk in GG carriers was high (OR = 1,1–2,3; p = 0,007) and in GA carriers was low (OR = 0,4–0,9; p = 0,01). LC risk was low (OR = 0,3–0,7; p = 0,0002) when both IgG-Bp and IgG-Es were absent. LC risk was high (OR = 1,8–4,4; p = 0,0001) when levels both IgG-Bp and IgG-Es were increased. IgG-Bp and IgG-Es formation was associated with TNFA (rs361525) gene polymorphism in HM (p = 0,007), and with IL1RNVNTR genepolymorphism (p = 0,003) and IL1B(rs16944) (p = 0,007) in LCP. There have first reported a relationship between cytokines gene polymorphisms and specific immune responses on chemical carcinogens and endogenous steroids in healthy donors and lung cancer patients. Immunoassays of IgG antibodies to Bp and Es combined with molecular-genetic studies of TNFA (rs361525), IL1RNVNTR and IL1B (rs16944) are recommended for the lung cancer risk assessment.
Keywords
About the authors
A. N. Glushkov
The Federal Research Center of Coal and Coal chemistry SBRAS (Institute of Human Ecology); Kemerovo State University
Author for correspondence.
Email: ihe@list.ru
MD, Professor, Director of Institute of Human Ecology
650065 Kemerovo, avenue Leningradsky, 10
Russian FederationE. G. Polenok
The Federal Research Center of Coal and Coal chemistry SBRAS (Institute of Human Ecology)
Email: fake@neicon.ru
PhD (Pharmacy), Chief of Immunochemistry Laboratory of Institute of Human Ecology
Kemerovo
Russian FederationL. A. Gordeeva
The Federal Research Center of Coal and Coal chemistry SBRAS (Institute of Human Ecology)
Email: fake@neicon.ru
PhD (Biology), Chief of Immunogenetics Laboratory of Institute of Human Ecology
Kemerovo Russian FederationS. A. Mun
The Federal Research Center of Coal and Coal chemistry SBRAS (Institute of Human Ecology)
Email: fake@neicon.ru
PhD (Medicine), Senior Research Fellow of the Immunogenetics Laboratory of Institute of Human Ecology
Kemerovo Russian FederationM. V. Kostyanko
Kemerovo State University
Email: fake@neicon.ru
Leading Engineer of the Organic Chemistry Chair of Institute of Fundamental Sciences
Kemerovo Russian FederationV. A. Titov
Regional Clinical Oncology Dispensary, Kemerovo
Email: fake@neicon.ru
Chief of Thoracic Department
Kemerovo Russian FederationE. N. Voronina
Institute of Chemical Biology and Fundamental Medicine SB RAS
Email: fake@neicon.ru
PhD (Biology), Research Fellow of Pharmacogenomics Laboratory
Novosibirsk Russian FederationA. I. Rogozin
Kemerovo State University
Email: fake@neicon.ru
Master of Genetics Chair of Institute of Biology, Ecology and Natural Resources
Kemerovo Russian FederationA. I. Voloshina
Kemerovo State University
Email: fake@neicon.ru
Master of Genetics Chair of Institute of Biology, Ecology and Natural Resources
Kemerovo Russian FederationI. A. Vafin
Regional Center of Blood, Kemerovo
Email: fake@neicon.ru
Main Physician
Kemerovo
Russian FederationS. E. Ragozhina
Regional Center of Blood, Kemerovo
Email: fake@neicon.ru
Assistant of Main Physician
Kemerovo
Russian FederationReferences
- Худолей В.В. Канцерогены: характеристики, закономерности, механизмы действия. Санкт-Петербург: НИИ Химии СПбГУ, 1990, 419 с. [Khudoley V.V. Carcinogens: characteristics, patterns, mechanisms of action. SRI of ChemistrySt.PbSU, St. Petersburg 1990, 419.]
- Wenger D., Gerecke A.C., Heeb N.V., Schmid P., Hueglin C., Naegeli H., Zenobi R. In vitro estrogenicity of ambientparticulatematter: contributionofhydroxylatedpolycyclicaromatichydro carbons. J. Appl. Toxicol. 2009, 29(3), 223–232.
- Богуш Т.А., Дудко Е.А., Беме А.А., Богуш Е.А., Ким А.И., Полоцкий Б.Е., Тюляндин С.А., Давыдов М.И. Эстрогеновые рецепторы, антиэстрогены и немелкоклеточный рак легкого. Биохимия 2010, 75(12), 1633–1641. [Bogush T.A., Dudko E.A., Beme A.A., Bogush E.A., Kim A.I., Polotsky B.E., Tjuljandin S.A., Davydov M.I. Estrogen receptors, antiestrogens, and non-small cell lung cancer. Biochemistry (Moscow) 2010, 75(12), 1633–1641.].
- Fucic A., Gamulin M., Ferencic Z., Rokotov D.S., Katic J., Bartonova A., Lovasic I.B., Merlo D.F. Lung cancer and environmental chemical exposure: a review of our current state of knowledge with reference to the role of hormones and hormone receptors as an increased risk factor for developing lung cancer in man. Toxicol. Pathol. 2010, 38(6), 849–855.
- De Buck S.S., Augustijns P., Muller C.P. Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers. J. Pharmacol. Experim. Therap. 2005, 313(2), 640–646.
- Grova N., Prodhomme E.J., Schellenberger M.T., Farinelle S., Muller C.P. Modulation of carcinogen bioavailability by immunization with benzo[a]pyrene – conjugate vaccines. Vaccine, 2009, 27(31), 4142–4151.
- Moolten F.L., Capparel N., Boger E. Reduction of respiratory tract binding of benzo(a)pyrene in mice by immunization. J. Natl. Cancer Inst. 1978, 61(5), 347–349.
- Peck R.M., Peck E.B. Inhibition of chemically induced neoplasia by immunization with an antigenic carcinogen-protein conjugate. Cancer Res. 1971, 31(11), 1550–1554.
- Silbart L.K., Keren D.F. Reduction of intestinal carcinogen absorption by carcinogen-specific immunity. Science, 1989, 243(4897), 1462–1464.
- Caldwell B.V., Tillson S.A., Esber H., Thorneycroft I.H. Survival of tumors after immunization against estrogens. Nature 1971, 231(14), 118–119.
- Kiyohara C., Horiuchi T., Takayama K., Nakanishi Y. IL1B rs1143634 polymorphism, cigarette smoking, alcohol use, and lung cancer risk in a Japanese population. J. Thorac. Oncol. 2010, 5(3), 299–304.
- Peng W., He Q., Yang J., Wang B., Lu M., Wang S., Wang J. Meta-analysis of association between cytokine gene polymorphism and lung cancer risk. Mol. Biol. Rep. 2012, 39(5), 5187–5194.
- Xu J., Yin Z., Cao S., Gao W., Liu L., Yin Y., Liu P., Shu Y. Systematic Review and Meta-Analysis on the Association between IL-1B Polymorphisms and Cancer Risk. PLoS One 2013, 8(5), e63654.
- Wang W., Chen J., Zhao F., Zhang Y.H. Lack association between a functional polymorphism (rs 1800796) in the interleukin –6 gene promoter and lung cancer. Diagn. Pathol. 2014, 9, 134.
- Глушков А.Н., Поленок Е.Г., Аносова Т.П., Савченко Я.А., Баканова М.Л., Минина В.И., Мун С.А., Ларин С.А., Костянко М.В. Сывороточные антитела к бензо[a]пирену и хромосомные аберрации в лимфоцитах периферической крови у рабочих углеперерабатывающего предприятия. Российский иммунологический журнал 2011, 5(14), 1, 39–44. [Glushkov A.N., Polenok E.G., Anosova T.P., Savchenko Ya.A., Bakanova M.L., Minina V.I., Mun S.A., Larin S.A., Kost’anko M.V. Serum antibodies to benzo[a]pyrene and chromosomal aberrations in lymphocytes peripheral blood at the workers of coal processing enterprise. Russian Immunological Journal 2011, 5(14), 1, 39–44.]
- Гордеева Л.А., Глушкова О.А, Воронина Е.Н., Шаталина И.В., Шутров А.Е., Попова О.С., Гареева Ю.В., Симонова Т.А., Сутулина И.М., Филипенко М.Л., Глушков А.Н. Ассоциации материнских полиморфизмов генов цитокинов (IL-1B, IL-1RN, TNF, IL-4, IL-6) с врожденными пороками развития у плода и новорожденного. Иммунология 2013, 34(6), 298–304 [Gordeeva L.A., Glushkova O.A., Voronina E.N., Shatalina I.V., Shutrov A.E., Popova O.S., Gareeva Yu.V., Simonova T.A., Sutulina I.M., Filipenko M.L., Glushkov A.N. Association of maternal polymorphisms of cytokine gene (IL1B, IL1RN, TNF, IL4, IL6) with congenital malformations in fetus and newborn. Immunology 2013, 34(6), 298–304.]
- Hajian-Tilaki K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. Caspian J. Intern. Med. 2013, 4(2), 627–635.